Vertex Pharmaceuticals Incorporated (VRTX) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Boston, MA, United States. Le PDG actuel est Reshma Kewalramani.
VRTX a date d'introduction en bourse 1991-07-24, 6,100 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $112.86B.
Vertex Pharmaceuticals Incorporated is a biotechnology company founded in 1989 and headquartered in Boston, Massachusetts, specializing in the development and commercialization of innovative therapies for serious diseases. The company has established a strong market presence in cystic fibrosis treatment with approved products including TRIKAFTA, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target patients with specific genetic mutations. Beyond cystic fibrosis, Vertex's clinical pipeline includes promising candidates for alpha-1 antitrypsin deficiency, kidney disease, Type 1 diabetes, neuropathic pain, and severe blood disorders, with programs ranging from Phase 1/2 to Phase 3 clinical trials. The company distributes its products through specialty pharmacies, specialty distributors, and hospital networks across the United States and internationally. Vertex maintains strategic collaborations with leading biotechnology and pharmaceutical partners including CRISPR Therapeutics, Moderna, Merck KGaA, and several other specialized therapy innovators to advance its research and development efforts.
